Special Zone Foundation: "Kolmar BNH Signs Trademark Transfer Agreement with Korea Atomic Energy Research Institute"

The Research and Development Special Zone Promotion Foundation (hereinafter referred to as the Special Zone Foundation) announced on the 25th that Kolmar BNH Co., Ltd. (hereinafter Kolmar BNH), the first research institute company, recently signed a trademark transfer agreement for "HemoHIM" with the Korea Atomic Energy Research Institute.

Lim Muntek, Head of Daedeok Research and Development Special Zone Headquarters at the Special Zone Foundation (left), is taking a commemorative photo after presenting a plaque of appreciation to Yoon Yewon, CEO of Kolmar BNH. Provided by the Research and Development Special Zone Promotion Foundation

Through this agreement, Kolmar BNH has secured independent brand competitiveness, laying the groundwork for its leap forward as a global health functional food company. This is a representative example that demonstrates the innovative achievements of the research institute company system.

In particular, the Special Zone Foundation emphasized that Kolmar BNH's acquisition of the trademark serves as a completed success model for research institute companies, following the sequence of "technology investment → KOSDAQ listing → equity sale → trademark transfer." It is expected to prompt research institute companies, universities, and public research institutions nationwide to recognize "commercialization through trademarks" as a new pathway to success.

Kolmar BNH was established in 2004 as the first research institute company through a joint venture between the Korea Atomic Energy Research Institute and Korea Kolmar Co., Ltd. "HemoHIM" is a health functional food developed to improve immune function, based on the Korea Atomic Energy Research Institute's "high-purity purification technology using radiation," and has surpassed a cumulative sales total of 3 trillion won this year.

With the transfer of the trademark, Kolmar BNH has achieved technological and brand independence from its parent research institution. As a result, the company is expected to reduce royalty costs and make swift decisions, enabling it to target the global market more effectively.

At the contract signing ceremony, Lim Muntek, Head of the Daedeok Research and Development Special Zone Headquarters at the Special Zone Foundation, presented a plaque of appreciation to Yoon Yowon, CEO of Kolmar BNH, in recognition of the company's contribution to establishing a successful model for technology commercialization by research institute companies.

Jung Heekwon, Chairman of the Special Zone Foundation, stated, "Kolmar BNH has demonstrated the effectiveness of the research institute company system. In particular, the transfer of the HemoHIM trademark is regarded as the first case of providing new momentum for the growth of companies based on public technology, and it will serve as a milestone for innovation not only for research institute companies but also for all advanced technology-based companies within the special zone in the future."

This content was produced with the assistance of AI translation services.